NASDAQ: ENSCEnsysce Biosciences Inc Stock
$7.77+0.77 (+11%)
Updated Jan 17, 2025
ENSC Price
$7.77
Fair Value Price
N/A
Market Cap
$10.14M
52 Week Low
$2.12
52 Week High
$30.90
P/E
-0.25x
P/B
1.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
-$9M
Beta
0.48
Next Earnings
Mar 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ENSC Overview
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENSC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Value
A
Growth
D
Momentum
C
Sentiment
D
Safety
C
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENSC
Ranked#233 of 557
Ranked#233 of 557
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.13 | A | |
| $121.18 | A | |
| $5.94 | A |
Be the first to know about important ENSC news, forecast changes, insider trades & much more!
ENSC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENSC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENSC is good value based on its book value relative to its share price (1.47x), compared to the US Biotechnology industry average (4.73x)
P/B vs Industry Valuation
ENSC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ENSC due diligence checks available for Premium users.
Valuation
ENSC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
-135.26x
Market
30.45x
ENSC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.47x
Industry
4.73x
ENSC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENSC's financial health
Profit margin
Revenue
$0.0
Net Income
$661.8k
Profit Margin
0%
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$2.8M
Debt to equity
0.41
ENSC's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENSC's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENSC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$0.0
Financing
$4.1M
ENSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENSC vs Biotech Stocks
Ensysce Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.